Iroko Pharmaceuticals to Present Phase 3 Data From Submicron NSAID Portfolio at American College of Rheumatology Annual Scientific Meeting
10/14/2013 9:42:11 AM
PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that data from Phase 3 studies of Iroko’s investigational non-steroidal anti-inflammatory drugs (NSAIDs) submicron diclofenac and submicron indomethacin will be presented in poster sessions at the upcoming 2013 American College of Rheumatology (ACR) Annual Scientific Meeting, taking place in San Diego, from October 25-30. Details of the poster sessions follow:
Help employers find you! Check out all the jobs and post your resume.